| 摘要 |
Crystallization of O-ethyl-O-(4-nitrophenyl)-phenylphosphonothioate is inhibited by maintaining therein between about 6 and about 12% by weight of bis-(O-4-nitrophenyl)-phenylphosphonothioate, optionally standardizing the active ingredient content to a predetermined level, preferably 80%, and or optionally destroying seed crystals present in the inhibited composition in order to extend the effectiveness of the crystallization inhibitor.
|
